Lyell Immunopharma, Inc. (LYEL) financial statements and ratios from SEC XBRL: revenue $36000.00 (TTM), net margin -762355.6%, revenue growth -50.0% YoY. Income statement, balance sheet, cash flow, and valuation. First-party data.
| Revenue (TTM) | $36000.00 |
| Net Margin | -762355.6% |
| Revenue Growth (YoY) | -50.0% |
| EPS Growth (YoY) | -33.6% |
| FCF Growth (YoY) | -1.3% |
| Price / Book | 1.63 |
| Price / Sales | 14085.92 |
| FCF Yield | -35.2% |
| Altman Z-Score | -6.17 (distress) |
| Sector P/E (Healthcare) | 21.7 |
LYEL overview · LYEL earnings · LYEL KPIs · LYEL investor relations · LYEL ownership · LYEL peers · LYEL filings
Data sourced from U.S. SEC EDGAR XBRL filings. Not personalized investment advice.